Teacher Retirement System of Texas Purchases 719 Shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA)

Teacher Retirement System of Texas boosted its position in shares of Kiniksa Pharmaceuticals, Ltd. (NASDAQ:KNSA) by 7.1% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 10,862 shares of the company’s stock after purchasing an additional 719 shares during the quarter. Teacher Retirement System of Texas’ holdings in Kiniksa Pharmaceuticals were worth $215,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Quarry LP bought a new position in shares of Kiniksa Pharmaceuticals in the third quarter worth approximately $50,000. China Universal Asset Management Co. Ltd. lifted its position in Kiniksa Pharmaceuticals by 12.9% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 8,814 shares of the company’s stock valued at $174,000 after acquiring an additional 1,004 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in Kiniksa Pharmaceuticals during the 3rd quarter valued at $189,000. Y Intercept Hong Kong Ltd bought a new stake in shares of Kiniksa Pharmaceuticals in the 4th quarter worth $258,000. Finally, New York State Common Retirement Fund lifted its holdings in shares of Kiniksa Pharmaceuticals by 12.4% during the fourth quarter. New York State Common Retirement Fund now owns 15,248 shares of the company’s stock valued at $302,000 after purchasing an additional 1,680 shares in the last quarter. 53.95% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Citigroup assumed coverage on Kiniksa Pharmaceuticals in a report on Thursday, March 13th. They issued a “buy” rating and a $40.00 price objective for the company. Wedbush reissued an “outperform” rating and set a $34.00 price objective on shares of Kiniksa Pharmaceuticals in a report on Tuesday, February 25th. Six investment analysts have rated the stock with a buy rating, According to data from MarketBeat, Kiniksa Pharmaceuticals has an average rating of “Buy” and an average target price of $37.17.

Insider Activity

In other news, CFO Mark Ragosa sold 8,879 shares of Kiniksa Pharmaceuticals stock in a transaction dated Wednesday, March 19th. The stock was sold at an average price of $23.10, for a total transaction of $205,104.90. Following the transaction, the chief financial officer now directly owns 23,382 shares of the company’s stock, valued at $540,124.20. The trade was a 27.52 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CAO Michael R. Megna sold 9,051 shares of the stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $22.45, for a total transaction of $203,194.95. Following the completion of the sale, the chief accounting officer now directly owns 26,528 shares of the company’s stock, valued at $595,553.60. This represents a 25.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 93,766 shares of company stock valued at $2,011,735 in the last 90 days. Company insiders own 54.57% of the company’s stock.

Kiniksa Pharmaceuticals Stock Performance

Shares of NASDAQ:KNSA opened at $21.85 on Thursday. The stock’s 50-day simple moving average is $20.96 and its two-hundred day simple moving average is $21.92. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -156.06 and a beta of 0.48. Kiniksa Pharmaceuticals, Ltd. has a 52-week low of $16.56 and a 52-week high of $28.15.

Kiniksa Pharmaceuticals (NASDAQ:KNSA) last posted its quarterly earnings data on Tuesday, February 25th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.06) by ($0.06). Kiniksa Pharmaceuticals had a negative return on equity of 7.31% and a negative net margin of 2.36%. The business had revenue of $122.50 million during the quarter, compared to analysts’ expectations of $123.42 million. During the same period in the previous year, the business posted $0.35 EPS. The business’s quarterly revenue was up 46.9% compared to the same quarter last year. As a group, equities analysts forecast that Kiniksa Pharmaceuticals, Ltd. will post -0.55 earnings per share for the current fiscal year.

About Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response.